Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Proteasome inhibition leads to accumulation of transcription factors, heat shock proteins, cyclins, and other
proteasome
substrate proteins by blocking their proteolytic degradation. An increase in gene transcription upon
proteasome
inhibition was found for a group of proteins, including p21(WAF1/CIP1), ubiquitin, and transcription factors. In this study, we have demonstrated selective up-regulation of
extracellular signal-regulated kinase 3
(
ERK3
) mRNA and protein expression upon treatment with peptide-based
proteasome
inhibitors or lactacystin.
ERK3
is a family member of the mitogen-activated protein kinases (also called ERK) that are key mediators of signal transduction from the cell surface to the nucleus.
ERK3
up-regulation is independent of the p53, Bcl2, and caspase 3 status of cells. p38 pathway kinase inhibitors prevent
proteasome
-dependent
ERK3
induction and enhance the antiproliferative effect of
proteasome
inhibitors. MCF-7 cells expressing
ERK3
ectopically show increased resistance toward
proteasome
inhibition. The results indicate that
ERK3
expression is a consequence of p38 pathway activation and most probably represents an intracellular defense or rescue mechanism against cell stress and damage induced by
proteasome
inhibition.
...
PMID:Proteasome- and p38-dependent regulation of ERK3 expression. 1114 4
Mitogen-activated protein (MAP) kinases are stable enzymes that are mainly regulated by phosphorylation and subcellular targeting. Here we report that
extracellular signal-regulated kinase 3
(
ERK3
), unlike other MAP kinases, is an unstable protein that is constitutively degraded in proliferating cells with a half-life of 30 min. The proteolysis of
ERK3
is executed by the
proteasome
and requires ubiquitination of the protein. Contrary to other protein kinases, the catalytic activity of
ERK3
is not responsible for its short half-life. Instead, analysis of ERK1/
ERK3
chimeras revealed the presence of two destabilization regions (NDR1 and -2) in the N-terminal lobe of the
ERK3
kinase domain that are both necessary and sufficient to target
ERK3
and heterologous proteins for proteasomal degradation. To assess the physiological relevance of the rapid turnover of
ERK3
, we monitored the expression of the kinase in different cellular models of differentiation. We observed that
ERK3
markedly accumulates during differentiation of PC12 and C2C12 cells into the neuronal and muscle lineage, respectively. The accumulation of
ERK3
during myogenic differentiation is associated with the time-dependent stabilization of the protein. Terminal skeletal muscle differentiation is accompanied by cell cycle withdrawal. Interestingly, we found that expression of stabilized forms of
ERK3
causes G(1) arrest in NIH 3T3 cells. We propose that
ERK3
biological activity is regulated by its cellular abundance through the control of protein stability.
...
PMID:Rapid turnover of extracellular signal-regulated kinase 3 by the ubiquitin-proteasome pathway defines a novel paradigm of mitogen-activated protein kinase regulation during cellular differentiation. 1280 96